aser in treatment of resistant melasma, Intradermal tranexamic acid in treatment of resistant melasma
Phase 2
Recruiting
- Conditions
- L81.1Melasma.Chloasma
- Registration Number
- IRCT20191011045057N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 27
Inclusion Criteria
Female patients with melasma with age ranging from 20 to 50 years
Having informed consent to participate in the study
No pregnancy or lactation
No systemic diseases
Exclusion Criteria
Female patients with melasma younger than 20 years and over 50 years
Lack of informed consent to participate in the study
Pregnancy or lactation
Systemic diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MASI score. Timepoint: Get started, one month later, two month later, three months later, three months after the end of treatment. Method of measurement: check list and examination.
- Secondary Outcome Measures
Name Time Method